BioWorld

July 18, 2006

View Archived Issues

Threshold Dives On Lack Of Efficacy In BPH Trials

Shares of Threshold Pharmaceuticals Inc. lost more than half their value after the company said it was dropping its benign prostatic hyperplasia drug, TH-070, following misses in Phase II and Phase III studies. (BioWorld Today) Read More

Actelion, Roche Sign $630M Autoimmunity Product Deal

Read More

Senate Scheduled To Take Vote Today On Pivotal ESC

Read More

Tigris Licenses Aminoflavone Prodrug For Cancer From NIH

Read More

Concert Pharma Brings In $10M Via Series A Round

Read More

Clinic Roundup

Read More

Other News To Note

Read More